– LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, is being evaluated in a Phase 1 study in advanced clear cell renal cell carcinoma at MD Anderson Cancer Center –

– LNK001 是一种靶向 CAIX 和 ENPP3 的 AND 门控 CAR-T 疗法，目前正在 MD 安德森癌症中心针对晚期透明细胞肾细胞癌开展一项 I 期临床研究 –

– Jie D'Elia, Ph.D., joins as Chief Executive Officer and Friedrich Graf Finckenstein, M.D., as Chief Medical Officer; co-founder Brian Slingerland becomes Executive Chair –

– Jie D'Elia 博士加入公司担任首席执行官，Friedrich Graf Finckenstein 医学博士担任首席医疗官；联合创始人 Brian Slingerland 出任执行董事长 –

– Series A financing upsized from $60 million to $90 million to advance a second solid tumor program in colorectal cancer and expand the pipeline –

– A轮融资额从6,000万美元上调至9,000万美元，以推进结直肠癌领域的第二个实体瘤项目并拓展产品管线 –

SOUTH SAN FRANCISCO, Calif. and AUSTIN, Texas

加利福尼亚州南旧金山和德克萨斯州奥斯汀

,

，

Sept. 28, 2026

2026年9月28日

/PRNewswire/ -- Link Cell Therapies ('Link'), an oncology cell therapy company utilizing its proprietary logic-gating technology to develop next-generation CAR-T therapeutics for solid tumors and hematologic malignancies, today announced that it has initiated clinical dosing for its lead program, LNK001.

/美通社/ -- 肿瘤细胞疗法公司Link Cell Therapies（“Link”）利用其专有的逻辑门控技术开发用于实体瘤和血液恶性肿瘤的下一代CAR-T疗法，今日宣布已启动其领先项目LNK001的临床给药。

The company also announced three additions to its executive leadership team and a $30 million expansion of its Series A financing..

该公司还宣布为其高管团队增加三名成员，并将其A轮融资扩大3,000万美元。

Initiated clinical dosing of LNK001

启动LNK001的临床给药

LNK001 is being evaluated in a Phase 1 study in patients with advanced or metastatic clear cell renal cell carcinoma ('RCC'). Clinical dosing has begun at MD Anderson Cancer Center.

LNK001 正在一项针对晚期或转移性透明细胞肾细胞癌（RCC）患者的 I 期临床试验中进行评估。MD 安德森癌症中心已开始临床给药。

LNK001 requires the co-expression of two antigens, CAIX and ENPP3, which are both highly expressed in most RCC tumors. CAIX has long been among the most attractive targets in RCC, but conventional CAR-T cells directed against it have been limited by on-target, off-tumor toxicity in the biliary epithelium, where CAIX is also expressed.

LNK001 需要同时表达两种抗原 CAIX 和 ENPP3，这两种抗原在大多数肾细胞癌（RCC）肿瘤中均高表达。CAIX 长期以来一直是 RCC 中最具吸引力的靶点之一，但针对它的传统 CAR-T 细胞疗法因在胆管上皮（CAIX 也在此处表达）中出现靶向非肿瘤毒性而受到限制。

By gating CAR-T activity on both antigens, LNK001 is designed to preserve the antitumor potential of CAIX targeting while sparing the healthy tissue that has constrained single-antigen approaches..

LNK001 通过对两种抗原实施 CAR-T 活性的门控控制，旨在保留靶向 CAIX 的抗肿瘤潜力，同时避免对限制单抗原疗法应用的健康组织造成损伤。

LNK001 is manufactured at CTMC, a joint venture between Resilience and The University of Texas MD Anderson Cancer Center. Additional clinical trial details are available at

LNK001 由 CTMC 生产，CTMC 是 Resilience 公司与德克萨斯大学 MD 安德森癌症中心成立的合资企业。更多临床试验详情可查阅

https://clinicaltrials.gov/study/NCT07564232

https://clinicaltrials.gov/study/NCT07564232

.

。

Leadership additions

领导层增补

Jie D'Elia, Ph.D., joins as Chief Executive Officer and a member of the Board of Directors. Dr. D'Elia was previously the CEO of SystImmune, Inc., a clinical-stage biopharmaceutical company focused on developing novel multi-specific antibodies and antibody-drug conjugates ('ADCs'). Before SystImmune, she spent eleven years at Bristol Myers Squibb ('BMS'), most recently as Senior Vice President of Business Development, Oncology, Hematology, and Cell Therapy.

Jie D'Elia 博士加入公司，担任首席执行官兼董事会成员。D'Elia 博士此前曾担任 SystImmune, Inc. 的首席执行官，该公司是一家处于临床阶段的生物制药企业，专注于开发新型多特异性抗体和抗体药物偶联物（ADC）。在加入 SystImmune 之前，她在百时美施贵宝（BMS）工作了十一年，最近担任的职务是肿瘤、血液学和细胞治疗业务开发高级副总裁。

During her tenure at BMS, she made a significant impact to BMS's pipeline evolution through multiple strategic partnerships and acquisitions in therapeutic areas ranging from oncology, hematology, cardiovascular, virology, and cell therapy. Prior to BMS, Dr. D'Elia served as the Vice President and Global Head of Business Development at Simcere Pharmaceutical, and held roles at AstraZeneca, Boston Consulting Group and Baxter Healthcare.

在百时美施贵宝（BMS）任职期间，她通过多项战略合作伙伴关系及收购项目，对BMS的产品管线演进产生了重大影响，涉及的治疗领域涵盖肿瘤学、血液学、心血管、病毒学及细胞疗法。加入BMS之前，D'Elia博士曾担任先声药业副总裁兼全球业务发展负责人，并在阿斯利康、波士顿咨询集团和百特医疗担任过职务。

Over the course of her career, she has led more than $40 billion in strategic partnerships and acquisitions. Dr. D'Elia holds a Ph.D. from the College of Pharmacy at the University of Texas at Austin and an MBA from Columbia Business School..

在她的职业生涯中，她主导了超过400亿美元的战略伙伴关系和收购。D'Elia博士拥有德克萨斯大学奥斯汀分校药学院的博士学位以及哥伦比亚商学院的工商管理硕士学位。

Brian Slingerland becomes Executive Chair. Brian co-founded Link in 2022 with Robbie Majzner, M.D., and Crystal Mackall, M.D., and has served on the Board of Directors. He previously co-founded and was the CEO of Stemcentrx, a next-generation ADC company that pursued novel targets with limited or no normal tissue expression, including DLL3 and SEZ6, and built the industry's first end-to-end ADC GMP manufacturing facility. Abbvie acquired Stemcentrx in 2016 for $6.2 billion, which at the time was the largest private acquisition of all time in biotechnology.

布莱恩·斯林格伦德（Brian Slingerland）出任执行董事长。布莱恩于2022年与罗比·马伊兹纳博士（Robbie Majzner, M.D.）和克里斯塔尔·麦卡尔博士（Crystal Mackall, M.D.）共同创立了Link公司，并一直担任董事会成员。他此前曾联合创立并担任Stemcentrx公司的首席执行官，这是一家下一代抗体药物偶联物（ADC）公司，致力于开发针对正常组织表达有限或无表达的 novel 靶点（包括DLL3和SEZ6），并建立了业界首个端到端的ADC GMP生产设施。艾伯维（AbbVie）于2016年以62亿美元收购Stemcentrx，该交易当时创下了生物技术领域有史以来最大的私人收购纪录。

Prior to founding Stemcentrx, Brian was a Founding Partner at Qatalyst Partners and Vice President at Goldman Sachs where he helped companies raise private venture capital, execute IPOs and other financings, advised on mergers and acquisitions, and gained valuable experience working with CEOs at various stages of development.

在创立Stemcentrx之前，Brian是Qatalyst Partners的创始合伙人，也是高盛集团的副总裁。在那里，他帮助公司筹集私人风险资本、执行首次公开募股（IPO）及其他融资活动，提供并购咨询建议，并在与处于不同发展阶段的CEO合作中积累了宝贵的经验。

Brian has held other biotechnology CEO roles, including of recently acquired Convergent Genomics, and Everest Detection, and served on the Boards of Directors and provided initial capital to multiple biotech companies including Enliven Therapeutics. Brian is a graduate of Virginia Tech..

布莱恩曾担任其他生物技术公司的首席执行官职务，包括最近被收购的Convergent Genomics和Everest Detection，并在多家生物技术公司（包括Enliven Therapeutics）的董事会任职并提供初始资本。布莱恩毕业于弗吉尼亚理工大学。

Friedrich Graf Finckenstein, M.D., joins as Chief Medical Officer. Dr Graf Finckenstein is a physician-scientist with decades of experience in clinical medicine, cancer research and drug development. Most recently, as Chief Medical Officer of Iovance Biotherapeutics he progressed the clinical portfolio of Tumor Infiltrating Lymphocyte (TIL) therapies across indications and next generation products and contributed to the approval of AMTAGVI.

弗里德里希·格拉夫·芬肯施泰因医学博士加入公司，担任首席医疗官。格拉夫·芬肯施泰因博士是一位医师科学家，在临床医学、癌症研究和药物开发方面拥有数十年的经验。此前，作为Iovance Biotherapeutics的首席医疗官，他推动了肿瘤浸润淋巴细胞（TIL）疗法在不同适应症及下一代产品方面的临床组合进展，并为AMTAGVI的获批作出了贡献。

®

®

(lifileucel) in the US, Canada and Australia as the first approved cell therapy for a solid tumor.  Before Iovance, he was Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development (pRED) in Basel, Switzerland. Earlier, he held clinical leadership roles at BMS, spanning early through late-stage development, including contributions to the approval of Opdivo.

（lifileucel）在美国、加拿大和澳大利亚获批，成为首款用于实体瘤的细胞疗法。在加入Iovance之前，他曾在瑞士巴塞尔的罗氏制药研究与早期开发部（pRED）担任全球肿瘤转化医学负责人。更早之前，他在百时美施贵宝（BMS）担任临床领导职务，负责从早期到后期的开发工作，并为Opdivo（纳武利尤单抗）的获批做出了贡献。

®

®

(nivolumab) in lung cancer. He holds a medical degree from the University of Hamburg, is a board-certified pediatrician and has conducted laboratory cancer research at the Ludwig Institute, San Diego Branch, the Children's Hospital Los Angeles and the University of Hamburg.

（纳武利尤单抗）在肺癌中的应用。他拥有汉堡大学的医学学位，是一名获得董事会认证的儿科医生，并曾在路德维希研究所圣地亚哥分部、洛杉矶儿童医院和汉堡大学进行过实验室癌症研究。

'From the beginning, our vision has been to translate this breakthrough science into therapies that can make a profound difference for people impacted by cancer,' said co-founder Robbie Majzner, M.D., of the Dana-Farber Cancer Institute and Harvard Medical School. 'Bringing in leaders with the experience, commitment and passion to advance our technology and execute at scale gives me tremendous confidence that we can realize that vision.'.

“从一开始，我们的愿景就是将这一突破性科学转化为能够为癌症患者带来深远影响的疗法，”联合创始人、来自丹娜—法伯癌症研究所和哈佛医学院的罗比·马伊兹纳博士表示。“引入具备经验、承诺和热情以推动我们的技术并实现规模化执行的领导者，使我对我们能够实现这一愿景充满信心。”

Abraham Bassan, Member of the Link Board of Directors and Partner at Samsara BioCapital, says 'We are excited about the strength and depth of the leadership team at Link. Their broad experience and commitment to advancing our science puts the company in an excellent position to develop a new generation of impactful medicines for patients.'.

Link董事会成员、Samsara BioCapital合伙人亚伯拉罕·巴桑表示：“我们对Link领导团队的实力与深度感到振奋。他们丰富的经验以及对我们科学推进的承诺，使公司处于极佳的位置，能够为患者开发新一代具有影响力的药物。”

Series A expansion to fund pipeline programs

A轮融资用于资助管线项目

Link's previously announced $60 million Series A financing led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and new investors including BMS, Kyowa Kirin, Sherpa Healthcare Partners, Western Technology Investment and the MD Anderson Cancer Focus Fund, was upsized to $90 million..

Link此前宣布的由强生公司通过其企业风险投资机构强生创新（Johnson & Johnson Innovation – JJDC, Inc.）领投的6000万美元A轮融资，已扩大至9000万美元。该轮融资还有创始投资者Samsara BioCapital和Sheatree Capital，以及Wing Venture Capital和新投资者包括BMS、Kyowa Kirin、Sherpa Healthcare Partners、Western Technology Investment和MD Anderson癌症焦点基金参与。

The additional capital will support clinical and preclinical development of additional logic gated CAR-T programs. Link's second solid tumor indication is colorectal cancer, where the company intends to begin a first-in-human trial in 2027 using a novel target pair co-expressed in the majority of colorectal tumors but absent from normal healthy tissues.

额外资本将支持更多逻辑门控CAR-T项目的临床和临床前开发。Link的第二项实体瘤适应症是结直肠癌，公司计划于2027年启动首次人体试验，采用一种新颖的靶点组合，该组合在大多数结直肠肿瘤中共同表达，但在正常健康组织中不存在。

Additional CAR-T programs in solid and hematologic cancers are in earlier development and will be advanced internally or through partnerships..

针对实体瘤和血液系统肿瘤的更多CAR-T项目正处于早期开发阶段，将通过内部推进或合作方式进一步发展。

'Link's logic-gate platform can make CAR-T broadly viable in solid tumors,' said Dr. D'Elia. 'A targeting approach that reliably distinguishes tumor from healthy tissue is what allows CAR-T to pursue in solid tumors the kind of deep and durable responses it has achieved in hematologic cancers. This financing lets us advance a pipeline built on that approach across additional tumor types.'.

“Link的逻辑门平台可使CAR-T疗法在实体瘤中广泛可行，”D'Elia博士表示。“一种能够可靠区分肿瘤组织与健康组织的靶向方法，使得CAR-T疗法能够在实体瘤中实现其在血液系统恶性肿瘤中已取得的深度且持久的疗效。此次融资使我们能够基于该方法，进一步拓展针对更多肿瘤类型的产品管线。”

About Link Cell Therapies

关于 Link 细胞疗法

Link Cell Therapies ('Link') is a biotechnology company based in South San Francisco, California, founded in 2022 by Robbie Majzner, M.D., and Crystal Mackall, M.D. at Stanford University, biotech entrepreneur Brian Slingerland, and Samsara BioCapital. Link's proprietary logic-gating technology allows for safe targeting of multiple antigens that are co-expressed selectively on cancer cells, thereby reducing the risk of on-target, off-tumor toxicity.

Link Cell Therapies（简称“Link”）是一家总部位于加利福尼亚州南旧金山的生物技术公司，由斯坦福大学的罗比·迈兹纳（Robbie Majzner）医学博士、克里斯塔尔·麦克尔（Crystal Mackall）医学博士、生物技术企业家布莱恩·斯林格兰德（Brian Slingerland）以及Samsara BioCapital于2022年共同创立。Link专有的逻辑门控技术能够安全地靶向在癌细胞上选择性共表达的多种抗原，从而降低靶向非肿瘤毒性风险。

This enables discovery of an entirely new landscape of 'clean' target pairs, and supports the development of next-generation CAR-T therapeutics for solid and hematologic cancers. Link's team features industry-leading scientists collaborating with top-tier advisors and life science financial and strategic investors committed to improving outcomes for cancer patients.

这使得发现全新的“干净”靶点对成为可能，并支持开发用于实体瘤和血液系统癌症的下一代CAR-T疗法。Link的团队汇聚了行业领先的科学家，他们与顶尖顾问以及致力于改善癌症患者预后结局的生命科学领域金融和战略投资者紧密合作。

To learn more, please visit .

欲了解更多信息，请访问。

www.linkcelltx.com

www.linkcelltx.com

.

。

Media Contact

媒体联系人

Link Cell Therapies

链接细胞疗法

[email protected]

[email protected]

SOURCE Link Cell Therapies

SOURCE Link 细胞疗法

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示